Over 850 patients in England diagnosed with NSCLC will be able to access the treatment in year one, with numbers tipped to rise to more than 1,000 patients in year three
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.